Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent...

Area of Science:

• Oncology
• Cancer Biology
• Metabolic Signaling

Background:

• Mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) are found in various cancers.
• These mutations lead to the production of 2-hydroxyglutarate (2-HG), a potential oncometabolite.
• The precise mechanisms by which mutant IDH and 2-HG promote tumorigenesis are not fully understood.

Purpose of the Study:

• To investigate the effects of endogenous IDH mutations and 2-HG on cancer development.
• To create and analyze isogenic cell lines with wild-type or mutant IDH1/2.
• To elucidate the signaling pathways involved in mutant IDH-driven tumorigenesis.

Main Methods:

• Generation of isogenic epithelial cell lines with wild-type or mutant IDH1/2.
• Assessment of 2-HG accumulation in response to IDH mutations.
• Analysis of epithelial-mesenchymal transition (EMT) markers, gene expression, and cellular morphology.
• Investigation of the role of ZEB1, miR-200 family, and sustained IDH1 expression in EMT.

Main Results:

• IDH1/2 mutations capable of high 2-HG production induced an EMT-like phenotype.
• 2-HG alone was sufficient to trigger aspects of this EMT-like phenotype.
• Mutant IDH-induced EMT was dependent on ZEB1 upregulation and miR-200 downregulation.
• Sustained IDH1 knockdown reversed EMT characteristics, indicating reversibility.

Conclusions:

• Mutant IDH proteins can reversibly deregulate signaling pathways contributing to tumorigenesis.
• The oncometabolite 2-HG plays a key role in mediating the EMT-like phenotype.
• Targeting mutant IDH or downstream pathways may offer therapeutic strategies for IDH-mutant cancers.